Skip to main content

Table 1 Patient characteristics (n = 33)

From: Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer

Median age

69 years

(Range, 53–80)

Clinical stage

T1c

20 (60.6%)

T2a

13 (39.4%)

Gleason score

6

12 (36.4%)

7

21 (63.6%)

Pretreatment PSA (ng/ml)

≤10

23 (69.7%)

10 – 20

10 (30.3%)

Risk stratification

Low

7 (21.2%)

Intermediate

26 (78.8%)

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us